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Few randomized trials have evaluated the use of non-invasive ventilation (NIV) for early acute 
respiratory failure (ARF) in non-intensive care unit (ICU) wards. The aim of this study is to test the 
hypothesis that early NIV for mild-moderate ARF in non-ICU wards can prevent development of 
severe ARF.  
Design 
Pragmatic, parallel group, randomized, controlled, multicenter trial. 
Setting 
Non-intensive care wards of tertiary centers. 
Patients 
Non-ICU ward patients with mild to moderate ARF without an established indication for NIV. 
Interventions 
Patients will be randomized to receive or not receive NIV in addition to best available care.  
Measurements and main results 
We will enroll 520 patients, 260 in each group. The primary endpoint of the study will be the 
development of severe ARF. Secondary endpoints will be 28-day mortality, length of hospital stay, 
safety of NIV in non-ICU environments, and a composite endpoint of all in-hospital respiratory 
complications. 
Conclusions 
This trial will help determine whether the early use of NIV in non-ICU wards can prevent 
progression from mild-moderate ARF to severe ARF. 
















Non-invasive ventilation (NIV), a technique to deliver positive pressure ventilation through a non-
invasive interface, is used worldwide to prevent and treat acute severe respiratory failure (ARF). 
(1–3) For this purpose, it is an intervention with a well-documented effect on survival in critically 
ill patients. (4) There are increasing reports on the effective use of NIV outside the ICU (5–9). In 
this regard, the use of NIV in general wards may be cost-effective (10) and may allow treatment of 
patients at an earlier stage of ARF. (3, 11)  
Moreover, it is logical to hypothesize that the use of NIV in the early phases of ARF (when ARF is 
mild to moderate in severity) may be beneficial for patients outside ICUs and may avoid the 
development of severe ARF with its associated need for ICU admission and invasive mechanical 
ventilation (MV). To date, however, randomized studies of such “early” NIV use for ARF are few 
and limited to the setting of immunocompromised patients. (12, 13) 
Accordingly, we designed a controlled trial to test the hypothesis that the addition of early NIV to 
standard care in patients with mild to moderate ARF could reduce the rate of disease progression.  
 
RATIONALE 
ARF is the most frequent cause of deterioration in hospitalized patients assessed by medical 
emergency teams. (14) There is good evidence of benefit with the use of NIV in specific etiologies 
of ARF such as acute exacerbation of chronic obstructive pulmonary disease (COPD) (15, 16) and 
cardiogenic pulmonary edema (17–19), and conflicting evidence in other causes of ARF, such as 
hypoxemic respiratory failure (20) and ARF in immunocompromised patients. (21-23) However, 















Most studies on the effect of NIV, however, have taken place in intensive care units (ICUs), as this 
is the appropriate setting for severe ARF and because in the ICU there is maximal expertise on 
ventilation and adequate equipment. Thus, the ICU environment provides safer and perhaps more 
effective treatment for patients with moderate or severe ARF. 
 
Use of NIV as an early therapy in mild to moderate ARF to prevent progression to severe ARF, 
albeit appealing, has been the object of only a few small trials and mixed evidence. A small trial 
conducted by Hilbert et al. on 52 patients found reduced intubation rates and increased survival in 
ICU patients treated with NIV compared to usual care in early ARF. (21) A second trial, involving 40 
ICU patients and comparing standard care with NIV in early ARF, showed that NIV was associated 
with a reduction in intubation rate, fatal complications and ICU length of stay, but not with better 
hospital survival. (25) More recently, however, Lemiale et al. performed a larger trial on 374 ICU 
patients, showing no difference in 28-day mortality between early NIV and standard care for ARF. 
(23) These trials, however, were all conducted in the ICU. 
 
Only two trials were conducted outside the ICU. Squadrone et al. randomized 40 patients on a 
hematology ward to either standard care or early use of NIV in ARF, showing a reduced 
progression of disease in the latter group. (12) Wermke et al. randomized 86 patients with ARF to 
standard therapy or standard therapy with the addition of NIV and found no difference in 
progression of disease or mortality. (13) However, as reported by the authors, these trials were 
underpowered to demonstrate differences between the two groups. 
In this regard, our trial will be the largest trial on the early use of NIV outside the ICU in patients 
with mild to moderate ARF, with greater power to demonstrate a difference in the rate of 















MATERIALS AND METHODS 
Study design, approval and registration 
We designed a parallel group, randomized, controlled, multicenter trial with a 1:1 allocation ratio. 
The study was approved by the Human Research Ethics  Committees of all participating centers 
and was registered on clinicaltrials.gov as NCT01572337 on April 6, 2012. 
Study aim 
The main aim of the study was to test whether the use of NIV in the early stages of ARF could 
reduce disease progression when compared to usual care. Secondary endpoints of the study 
aimed to evaluate the impact of early NIV on 28-day mortality and on length of hospital stay. 
Study population/Participants 
We will enroll 520 adult patients with mild to moderate ARF admitted to a non-intensive-care 
ward. The inclusion and exclusion criteria are summarized in Table 1. Contraindications to NIV 
include respiratory arrest, inability to fit mask, hypotensive shock, ongoing cardiac ischemia or 
arrhythmia, copious upper gastrointestinal bleeding, uncooperating patient, inability to protect 
airway, swallowing impairment, excessive secretions, multiple organ failure, recent facial, upper 
airway or upper gastrointestinal surgery, facial trauma/burns, life threatening hypoxemia, 
vomiting, bowel obstruction, undrained pneumothorax. (3,26) The aim of these criteria is to 
identify a group of patients with very early mild to moderate ARF and to exclude those patients 
who have an already established clear indication for NIV. The only etiologic exclusion criteria is 
COPD exacerbation (in which NIV is considered mandatory); in all other cases, inclusion and 
















The study procedure is summarized in Figure 1. Patients with mild to moderate ARF (defined as at 
least one of the following criteria: radiological evidence of new pulmonary consolidation or 
atelectasis; peripheral oxygen saturation <92% while breathing room air or PaO 2/FiO2 ratio < 300 
but >200 on arterial blood gas analysis; decompensated hypercapnia (pCO2 > 45 mmHg and pH < 
7.35) or clinical signs of respiratory distress (dyspnea, utilization of accessory respiratory muscles, 
paradoxical movement of thoraco-abdominal wall) on room air will be screened for eligibility. If 
eligible, they will then be approached to explain the study protocol and obtain written informed 
consent. Once the informed consent has been signed, patients will be allocated to each study 
group according to a web-based centralized randomization service with the use of a permuted-
block design stratified according to center. Data will be collected by trained observers who will not 
participate in patient care.  
 
Patients randomized to the “usual care” group will receive the best available treatment currently 
in use in the institution, including oxygen therapy, diuretics, antibiotics and other therapies to 
treat the underlying cause of the ARF. Patients in this group will not receive NIV treatment unless 
the medical emergency team deems it necessary. If NIV is administered outside of such 
restrictions, this will represent a protocol violation.  
Patients assigned to the “early NIV” group will receive the same best available treatment as the 
“standard” group, together with two-hour cycles of NIV every eight hours.. Oro-nasal, full-face and 
helmet NIV interface will be allowed. The preferred NIV treatment will be CPAP (PEEP 5 to 8 
cmH2O) unless the ARF is hypercapnic at enrollment or in the following days. In such cases 
pressure support ventilation (with a pressure support of 10 to 20 cmH2O) will be added. 
Ventilatory parameters will be set (and then modified if required) by physicians on the basis of 














reaching a peripheral oxygen saturation >92% and PaCO2 <45 mmHg, without restrictions, 
according to the pragmatic nature of the study. Chosen settings will be recorded.  
The Medical Emergency Team (MET) was responsible for setting-up and initial deliver of NIV in 
accordance with the physicians of the ward. MET always included an anesthesiologist-intensivist 
and a nurse and/or a fellow, differing in the various participating hospitals). Monitoring of 
uncomplicated patients is performed by the ward staff. 
Patients will be evaluated before starting each NIV cycle. Treatment with NIV will continue until at 
least one of the following criteria is met: 
 Clinical improvement determined by the resolution of inclusion criteria; 
 Patient refusal of treatment due to intolerance, or consent withdrawal; 
 Clinical decision of NIV interruption for NIV contraindication or other reasons  
 Development of severe ARF defined by one or more of the following criteria: 
o Hypercapnic acidemia (PaCO2 > 45 mmHg and pH < 7.30) 
o Severe gas transfer deficit (PaO2/FiO2 < 200) 
o Persistent respiratory distress (persistent marked dyspnea, use of accessory 
respiratory muscles, paradoxical respiratory movements) 
 Post-randomization decision/diagnosis of extremely poor short-term prognosis (imminent 
death with decision for palliative treatment only), with withdrawal of non-palliative 
treatment; 
 Need for immediate invasive mechanical ventilation 
 ICU admission 
 Death 
Treatment with NIV will last for at least 24 hours (3 cycles) unless interruption criteria (with the 














Target peripheral oxygen saturation will be 92-95% in both groups. Clinical re-evaluation (inclusive 
of re-checking for inclusion and exclusion criteria) will be performed daily by the medical 
emergency team or more often if deemed necessary by the ward physicians.  
As the protocol is carried in general wards, an arterial catheter is never positioned. Arterial blood 
gas analyses are only performed upon clinical judgement by means of single shot arterial 
punctures. 
NIV treatment will continue for 4-day periods. At the end of each period, patients will undergo a 6-
h screening test during which they will breath room air. If their SaO2 decreases below 95%, or the 
respiratory rate increases to > 25 breaths/min, patients will be returned to the assigned treatment 
for another 4-day period. The treatment protocol will be discontinued when the patient has a 
SaO2 > 95% and respiratory rate < 25 breaths/min. (12) This does not apply to patients who have 
already reached the primary endpoint or one of the above-mentioned reasons for NIV 
discontinuation. (Figure 2) 
 
Data collection 
We will collect demographic data (age, sex), as well as baseline pathophysiological data (height, 
weight, comorbidities). Two independent Investigators will assess and record the main cause of 
acute respiratory failure, as well as concomitant causes and the therapy the patient is receiving. 
Vital signs (respiratory rate, peripheral oxygen saturation, Glasgow Coma Score, arterial blood 
pressure, heart rate) and arterial blood gas data (where available) will be recorded at all scheduled 
time points if the patient will be not yet discharged from the hospital. Information on ventilator 
parameters, along with complications and potential contraindications to NIV treatment, will also 
be collected. 















Individual participant data that underlie the results reported in the trial’s final results  article, after 
deidentification, agreement of the privacy office of the Institute and ethical committee approval  
will be shared upon request 9 months to five years after the publication of the trial’s final results.  
Study protocol and informed consent form will also be available upon request. Requesters must 
have a demonstrated experience in medical research, with no conflict of interest that may 
potentially influence their interpretation of any analyses . The data sharing will be only for the 
purposes of health and medical research and within the constraints of the consent under which 
the data were originally gathered. Requester will be required to enter into a Data Sharing 
Agreement which will follow the Ethical Committee and Privacy Office updated indications 
Study endpoints/ Outcomes 
According to the recommendations of the European Society of Anaesthesiology (ESA) and the 
European Society of Intensive Care Medicine (ESICM) joint task force (27), the study will also focus 
on clinically relevant outcomes such as mortality, need for invasive mechanical ventilation, length 
of hospital stay and ICU admission.  
 
The primary outcome will be the development of severe ARF defined by one or more of the 
criteria described above. Prespecified subgroups analyses for the primary endpoint will be: age<75 
years old; 20<=BMI<30 kg/m2; respiratory rate<25 per minute; postoperative patients . 
 
Secondary outcomes will include 28-day mortality, length of hospital stay, as well as a composite 
endpoint of all in-hospital respiratory complications (comprising atelectasis, nosocomial 
pneumonia, new pneumothorax, pleural effusion, intubation, tracheostomy and acute respiratory 















Atelectasis will be defined as lung opacification with a shift of the mediastinum, hilum or hemi-
diaphragm, and compensatory over inflation in the adjacent non- atelectatic lung. (29) 
Nosocomial pneumonia will be defined as two or more serial chest radiographs with at least one 
of the following findings (one radiograph is sufficient for patients with no underlying pulmonary or 
cardiac disease): (i) New or progressive and persistent infiltrates, (ii) consolidation, (iii) cavitation; 
AND at least one of the following: (a) fever (>38 °C) with no other recognized cause, (b) leukopenia 
(white cell count <4x109/liter) or leukocytosis (white cell count >12x109/liter), (c) for >70-year old 
adults, altered mental status with no other recognized cause; AND at least two of the following: 
(a) new onset of purulent sputum or change in character of sputum, or increased respiratory 
secretions, or increased suctioning requirements, (b) new onset or worsening cough, or dyspnea, 
or tachypnoea, (c) rales or bronchial breath sounds, (d) worsening gas exchange (hypoxemia, 
increased oxygen requirement, increased ventilator demand) occurring more than 48 hours after 
hospital admission and not appearing to be incubating at the time of admission. (30) 
Pneumothorax will be defined as air in the pleural space with no vascular markings surrounding 
the visceral pleura. (29) 
Pleural effusion will be defined as chest X-ray demonstrating blunting of the costo-phrenic angle, 
loss of the sharp silhouette of the ipsilateral hemi-diaphragm when upright, displacement of 
adjacent anatomical structures, or a hazy opacity in one hemithorax with preserved vascular 
shadows when supine. (29) 
 
Statistical analysis and sample size estimates 
Data will be collected by the investigators and stored electronically in a digital Excel spreadsheet 
(version 2010, Microsoft Corporation, Redmond, WA, USA) and analyzed using STATA (Stata 














an epidemiologist. All analysis will be performed by an independent statistician blinded to 
intervention allocation. We will not apply any imputation for missing data. All data will be 
analyzed according to the intention-to-treat principle. The only exception will be those patients 
that, after randomization, are declared terminally ill and only receive palliative interventions: this 
decision will be taken as standard practice by the MET in conjunction with the caring ward staff 
and shared with the patient and his/her family. 
Demographic and baseline disease characteristics will be summarized with the use of descriptive 
statistics. Categorical variables will be reported as absolute numbers and percentages. Unadjusted 
univariate analyses to compare the two groups will be performed using Pearson’s χ2 test or 
Fisher’s exact test as appropriate. Risk differences and 95% confidence intervals will be calculated 
by means of the two-by-two table. Continuous variables will be reported as mean ± standard 
deviation or median and interquartile range, based on the distribution. Normality will be 
evaluated with the Shapiro-Wilk normality test, along with visual histogram evaluation and a Q-Q 
plot, and differences between groups will be tested using Student’s T test or the Wilcoxon signed 
rank test, as appropriate. 
A logistic regression model using a stepwise selection will be used to estimate the treatment 
effect with respect to primary and secondary endpoints and predictors of mortality. The pre-
randomization clinical data (e.g. demographic and baseline pathophysiological data) and center 
will be entered into the model if their univariate p value is less than 0.2. Collinearity and 
overfitting will be assessed using a stepwise regression model and Pearson correlation test. The 
treatment group will be forced into the multivariate model. A classic logistic regression will be 
performed with a consistent number of events and the number of covariates in the model will be 
decided based on the number of outcome events. In the multivariate analyses, clinical factors or 














We will compare patients receiving NIV with those assigned to standard care for time to event 
with the log-rank test and display such comparison with Kaplan-Meier survival curves. A time to 
event analysis with a Cox regression will be performed to adjust for key baseline characteristics . 
Two interim analyses performed by an independent safety committee after recruiting 25% (n=130) 
and 50% (n=260) of patients are planned. Data evaluation at each interim analysis will be based on 
the alpha spending function concept, according to DeMets, (31) and will employ O’Brien-Fleming 
Z-test boundaries. (32) During the first interim analysis the efficacy stopping rule will require a p 
value (p < 0.005), while a higher value (p < 0.014) will be required for the second analysis. 
Investigators will be kept blind to the interim analysis results. 
The independent safety committee will also perform conditional power analyses in order to 
evaluate potential interruption for futility issues in the trial. Conditional power will be calculated 
by assuming that the proportion of outcomes will follow the observed trend. 
Based on available literature,(12,13) we have hypothesized that the primary endpoint will be 
reached by 22% of patients in the “usual care” group and in 11% of patients in the “early-NIV” 
group. We based the sample size computation on a two-sided alpha error of 0.05 and a power of 
90% using Pearson’s χ2 test. Therefore, we calculated 256 patients per group using the continuity 
correction (260 considering possible protocol deviations) for a total of 520 patients.  
 
Monitoring of the study 
 
Study auditors will verify the strict adherence to the clinical trial protocol and will confirm accurate 
data collection according to Good Clinical Practice guidelines. (33) Study monitoring and follow-up, 

















It is important to evaluate the role of early initiation of NIV in addition to standard therapy as this 
may prevent progression to severe ARF in patients, as previously reported, (12,15,33) and 
consequently might improve outcomes and reduce healthcare costs. 
The exclusion of patients with acute exacerbation of COPD is due to the fact that NIV is first-line 
therapy in these patients (26) and it would be unethical to deprive them of this treatment. Data 
will be stored in an electronic database with no patient identifiers (a unique numeric code will be 
used) to address privacy issues. 
 
Study initiation, timing and participating centers, source of funding 
The study started after Ethical Committee approval from each contributing recruiting center. 
Recruitment started in April 2012 as a single center trial to assess feasibility. The study became 
multicentric in 2016. Consecutive participants who meet eligibility criteria and sign the written 
informed consent are enrolled. The study progress will be updated monthly. Currently, six 
hospitals have randomized a total of 175 patients. 
The authors are solely responsible for the design and conduct of the study, all study analyses and 
drafting and editing of the final research paper. 
The trial is funded with departmental funds only. 
 
EXPECTED RESULTS 
In the present study, we will test the hypothesis that the early addition of NIV in non-ICU patients 














help determine whether NIV can play a wider role in the treatment of ARF than it currently does, 
possibly reducing short-term mortality and length of hospital stay. 
Limitations 
A possible limitation of the study is the absence of a strictly defined “usual care” in the control 
group, leaving the definition of best available treatment to the single participating centers. We 
believe, however, that this pragmatic approach can also be seen as a strength of our study, which 
will allow us to capture the complex reality of tertiary centers and allow each patient to be treated 
according to best available local expertise and logistics. In this context, for example, 
echocardiography is only performed in those with a positive history or clinical features of cardiac 
dysfunction (severe right ventricular dysfunction is a contraindication to NIV)  and lung ultrasound 
for pleural effusion is only performed at discretion of clinicians caring for the patients . 
Moreover, as the study will take place in ordinary, non-intensive general medical or surgical 
wards, that do not have the resource and staffing of ICUs, we anticipate that the adherence to 
study protocols, both by patients and by staff, may not be perfect. However, we believe this is also 
a potential strength of the study, as it would investigate and measure use of NIV in a “real world” 
environment and not solely as part of a tightly controlled experimental protocol. Furthermore, 
due to the nature of NIV treatment, blinding is not an option in this setting. Also, the exclusion 
criteria cut out from the present study some of the patients who might benefit more from NIV: 
COPD exacerbation. As NIV has been already demonstrated extremely beneficial in this setting, in 
many centers, it is used immediately as first-line therapy in this population. Therefore, we decided 
to exclude these patients, even if this may reduce the magnitude of our findings. However, this 
might be seen as a strength more than a limitation, as it'is more ethical and improves the validity 
of our eventual positive findings. Lastly, the hypothesized effect size might be considered too big, 














sample size should have been 49 patients per group only and following the results of Wermke et 
al., (13) the sample size should have been 213 per group. Our prudential decision of enrolling 520 




This will be the first large randomized controlled trial performed outside the ICU and comparing 
the effect of the early addition of NIV to usual care in patients with mild to moderate ARF. 
Evidence resulting from this study will potentially be of value in the effective early management of 
patients with ARF. 
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Table 1 – Inclusion and Exclusion criteria. 
Inclusion criteria (all three have to be 
present) 
 
Exclusion criteria (one is sufficient to 
exclude the patient) 
 
 Age > 18 years; 
 Admission to non-intensive-care 
department; 
 Mild to moderate ARF, defined as at 
least one of the following: 
o Radiological evidence of new 
pulmonary consolidation or 
atelectasis; 
o Peripheral oxygen saturation <92% 
while breathing room air or 
PaO2/FiO2 ratio < 300 on arterial 
blood gas analysis; 
o Decompensated hypercapnia (pCO2 
> 45 mmHg and pH < 7.35); 
o Clinical signs of respiratory distress 
(dyspnea, utilization of accessory 
respiratory muscles, paradox 
movements of thoraco-abdominal 
wall) on room air. 
 Refusal to sign informed consent 
 Respiratory failure due to COPD 
exacerbation (PaCO2 > 45 mmHg and 
pH < 7.35); 
 Severe, hypercapnic ARF defined as 
PaCO2 > 45 mmHg and pH <7.30; 
 Severe, hypoxic ARF defined as 
PaO2/FiO2 <200; 
 Need for immediate mechanical 
ventilation or ICU as judged by the ICU 
physician in charge; 
 Extremely poor short-term prognosis 
(imminent death with decision for 
palliative treatment only); 
 Invasive or non-invasive mechanical 
ventilation during the same 
hospitalization due to respiratory 
failure. 



















Figure 1 Study procedure flowchart. NIV – Non-invasive ventilation. 
Figure 2 Intervention diagram. 
ACCEPTED MANUSCRIPT
Figure 1
Figure 2
